Literature DB >> 27643385

RORγt antagonist suppresses M3 muscarinic acetylcholine receptor-induced Sjögren's syndrome-like sialadenitis.

M Tahara1, H Tsuboi1, S Segawa1, H Asashima1, M Iizuka-Koga1, T Hirota1, H Takahashi1, Y Kondo1, M Matsui2, I Matsumoto1, T Sumida1.   

Abstract

We showed recently that M3 muscarinic acetylcholine receptor (M3R)-reactive CD3+ T cells play a pathogenic role in the development of murine autoimmune sialadenitis (MIS), which mimics Sjögren's syndrome (SS). The aim of this study was to determine the effectiveness and mechanism of action of retinoic acid-related orphan receptor-gamma t (RORγt) antagonist (A213) in MIS. Splenocytes from M3R knockout (M3R-/- ) mice immunized with murine M3R peptide mixture were inoculated into recombination-activating gene 1 knockout (Rag-1-/- ) mice (M3R-/- →Rag-1-/- ) with MIS. Immunized M3R-/- mice (pretransfer treatment) and M3R-/- →Rag-1-/- mice (post-transfer treatment) were treated with A213 every 3 days. Salivary volume, severity of sialadenitis and cytokine production from M3R peptide-stimulated splenocytes and lymph node cells were examined. Effects of A213 on cytokine production were analysed by enzyme-linked immunosorbent assay (ELISA) and on T helper type 1 (Th1), Th17 and Th2 differentiation from CD4+ T cells by flow cytometry. Pretransfer A213 treatment maintained salivary volume, improved MIS and reduced interferon (IFN)-γ and interleukin (IL)-17 production significantly compared with phosphate-buffered saline (PBS) (P < 0·05). These suppressive effects involved CD4+ T cells rather than CD11c+ cells. Post-transfer treatment with A213 increased salivary volume (P < 0·05), suppressed MIS (P < 0·005) and reduced IFN-γ and IL-17 production (P < 0·05). In vitro, A213 suppressed IFN-γ and IL-17 production from M3R-stimulated splenocytes and CD4+ T cells of immunized M3R-/- mice (P < 0·05). In contrast with M3R specific responses, A213 suppressed only IL-17 production from Th17 differentiated CD4+ T cells without any effect on Th1 and Th2 differentiation in vitro. Our findings suggested that RORγt antagonism is potentially suitable treatment strategy for SS-like sialadenitis through suppression of IL-17 and IFN-γ production by M3R-specific T cells.
© 2016 British Society for Immunology.

Entities:  

Keywords:  M3 muscarinic acetylcholine receptor; RORγt antagonist; Sjögren's syndrome; sialadenitis

Mesh:

Substances:

Year:  2016        PMID: 27643385      PMCID: PMC5217906          DOI: 10.1111/cei.12868

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Pathogenic role of immune response to M3 muscarinic acetylcholine receptor in Sjögren's syndrome-like sialoadenitis.

Authors:  Mana Iizuka; Ei Wakamatsu; Hiroto Tsuboi; Yumi Nakamura; Taichi Hayashi; Minoru Matsui; Daisuke Goto; Satoshi Ito; Isao Matsumoto; Takayuki Sumida
Journal:  J Autoimmun       Date:  2010-09-22       Impact factor: 7.094

2.  ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes.

Authors:  Laura A Solt; Subhashis Banerjee; Sean Campbell; Theodore M Kamenecka; Thomas P Burris
Journal:  Endocrinology       Date:  2015-01-05       Impact factor: 4.736

3.  Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome.

Authors:  S Bacman; A Berra; L Sterin-Borda; E Borda
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-02       Impact factor: 4.799

4.  ILC1 populations join the border patrol.

Authors:  Kevin J Maloy; Holm H Uhlig
Journal:  Immunity       Date:  2013-04-18       Impact factor: 31.745

5.  M3 muscarinic acetylcholine receptor reactive IL-17 producing T cells promotes development of Sjögren's syndrome like sialadenitis.

Authors:  Mana Iizuka; Hiroto Tsuboi; Hiromitsu Asashima; Tomoya Hirota; Yuya Kondo; Minoru Matsui; Isao Matsumoto; Takayuki Sumida
Journal:  Mod Rheumatol       Date:  2014-03-04       Impact factor: 3.023

6.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

7.  Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells.

Authors:  Anja Fuchs; William Vermi; Jacob S Lee; Silvia Lonardi; Susan Gilfillan; Rodney D Newberry; Marina Cella; Marco Colonna
Journal:  Immunity       Date:  2013-02-28       Impact factor: 31.745

8.  Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.

Authors:  Jacques-Eric Gottenberg; Gael Cinquetti; Claire Larroche; Bernard Combe; Eric Hachulla; Olivier Meyer; Edouard Pertuiset; Guy Kaplanski; Laurent Chiche; Jean-Marie Berthelot; Bruno Gombert; Philippe Goupille; Christian Marcelli; Séverine Feuillet; Jean Leone; Jean Sibilia; Charles Zarnitsky; Philippe Carli; Stephanie Rist; Philippe Gaudin; Carine Salliot; Muriel Piperno; Adeline Deplas; Maxime Breban; Thierry Lequerre; Pascal Richette; Charles Ghiringhelli; Mohamed Hamidou; Philippe Ravaud; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2012-12-21       Impact factor: 19.103

9.  The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat.

Authors:  Nicolas Manel; Derya Unutmaz; Dan R Littman
Journal:  Nat Immunol       Date:  2008-05-04       Impact factor: 25.606

10.  Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks.

Authors:  Hiroto Tsuboi; Isao Matsumoto; Shinya Hagiwara; Tomoya Hirota; Hiroyuki Takahashi; Hiroshi Ebe; Masahiro Yokosawa; Chihiro Hagiya; Hiromitsu Asashima; Chinatsu Takai; Haruka Miki; Naoto Umeda; Yuya Kondo; Hiroshi Ogishima; Takeshi Suzuki; Shintaro Hirata; Kazuyoshi Saito; Yoshiya Tanaka; Yoshiro Horai; Hideki Nakamura; Atsushi Kawakami; Takayuki Sumida
Journal:  Mod Rheumatol       Date:  2014-09-11       Impact factor: 3.023

View more
  6 in total

1.  Salivary gland immunization via Wharton's duct activates differential T-cell responses within the salivary gland immune system.

Authors:  Guangliang Liu; Fangfang Zhang; Ruixue Wang; Steven D London; Lucille London
Journal:  FASEB J       Date:  2019-02-28       Impact factor: 5.834

Review 2.  Interferons and Dry Eye in Sjögren's Syndrome.

Authors:  Yoko Ogawa; Eisuke Shimizu; Kazuo Tsubota
Journal:  Int J Mol Sci       Date:  2018-11-10       Impact factor: 5.923

Review 3.  T Helper 17 Cells in Primary Sjögren's Syndrome.

Authors:  Kiyoshi Matsui; Hajime Sano
Journal:  J Clin Med       Date:  2017-07-05       Impact factor: 4.241

Review 4.  Review: Transcriptional Regulation of CD4+ T Cell Differentiation in Experimentally Induced Arthritis and Rheumatoid Arthritis.

Authors:  Yuya Kondo; Masahiro Yokosawa; Shunta Kaneko; Kotona Furuyama; Seiji Segawa; Hiroto Tsuboi; Isao Matsumoto; Takayuki Sumida
Journal:  Arthritis Rheumatol       Date:  2018-03-13       Impact factor: 10.995

Review 5.  Recent Advances in Mouse Models of Sjögren's Syndrome.

Authors:  Yunzhen Gao; Yan Chen; Zhongjian Zhang; Xinhua Yu; Junfeng Zheng
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

Review 6.  Modulation of Apoptosis by Cytotoxic Mediators and Cell-Survival Molecules in Sjögren's Syndrome.

Authors:  Hideki Nakamura; Yoshiro Horai; Toshimasa Shimizu; Atsushi Kawakami
Journal:  Int J Mol Sci       Date:  2018-08-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.